Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms.
about
Mechanisms and therapeutic applications of electromagnetic therapy in Parkinson's diseaseBasal ganglia activity patterns in parkinsonism and computational modeling of their downstream effectsHigh frequency stimulation of the subthalamic nucleus leads to presynaptic GABA(B)-dependent depression of subthalamo-nigral afferentsCurrent Experimental Studies of Gene Therapy in Parkinson's DiseaseMechanism of parkinsonian neuronal oscillations in the primate basal ganglia: some considerations based on our recent work.Image-guided convection-enhanced delivery of muscimol to the primate brainBL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated miceDeep brain stimulation does not silence neurons in subthalamic nucleus in Parkinson's patientsAn inexpensive drivable cannulated microelectrode array for simultaneous unit recording and drug infusion in the same brain nucleus of behaving ratsDeep brain stimulation of the subthalamic nucleus in Parkinson's disease: evaluation of active electrode contacts.Mechanisms of deep brain stimulation for obsessive compulsive disorder: effects upon cells and circuitsGene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.Mechanism of Deep Brain Stimulation: Inhibition, Excitation, or Disruption?Dynamics of the subthalamo-pallidal complex in Parkinson's disease during deep brain stimulationThe temporal pattern of stimulation may be important to the mechanism of deep brain stimulationNeural origin of evoked potentials during thalamic deep brain stimulation.Intraventricular and intracerebral delivery of anti-epileptic drugs in the kindling model.Striatal mechanisms underlying movement, reinforcement, and punishment.Gene-based therapies in Parkinson's disease.Disrupting neuronal transmission: mechanism of DBS?Gene therapy for Parkinson's disease: where are we now and where are we going?Progress in gene therapy for neurological disorders.Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indicationsReassessing models of basal ganglia function and dysfunction.Promising therapeutic agents for the treatment of Parkinson's disease.Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease.Advances in optogenetic and chemogenetic methods to study brain circuits in non-human primates.Use of intraoperative local field potential spectral analysis to differentiate basal ganglia structures in Parkinson's disease patients.Increased gamma oscillatory activity in the subthalamic nucleus during tremor in Parkinson's disease patients.Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia.Topography of dyskinesias and torticollis evoked by inhibition of substantia nigra pars reticulata.Adenoviral clostridial light chain gene-based synaptic inhibition through neuronal synaptobrevin elimination.Inactivation of the PVN during hypoglycemia partially simulates hypoglycemia-associated autonomic failure.Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism.D2-like dopamine receptors modulate SKCa channel function in subthalamic nucleus neurons through inhibition of Cav2.2 channels.Neuronal inhibition and synaptic plasticity of basal ganglia neurons in Parkinson's disease.Quantitative theory of deep brain stimulation of the subthalamic nucleus for the suppression of pathological rhythms in Parkinson's disease.Gene therapy for Parkinson's disease
P2860
Q26782971-2E2C4E21-3462-4F43-BE58-8DC98EAD2EB0Q28271277-1E75849F-94F4-42E2-BEDA-9E87CBF0F1BBQ28537953-003A1DAA-264D-412E-90E0-17AE43F8F3C1Q33627771-6CC14152-A61C-406F-BD7D-5B0C908B5474Q33658765-E688C60E-8A98-4613-B8A2-2B9C18FAA4E8Q33785767-38E53E3D-1F83-4566-857A-33B6EDF9C96EQ34762041-9834270F-51DC-4B68-9EFC-519E8D5DD781Q35122590-146E4E0E-A882-4470-BD88-A84B79FDE96AQ35160545-BFEE5B39-FDF0-4324-8C68-C92DA0581CDBQ35475589-9316D57F-865E-4A29-B61B-6D1762CB5CB8Q36031467-98B40DFA-5B73-40F8-814E-A55A9522DA5BQ36150495-B83904F8-62E1-425F-A392-22663AE3C460Q36912305-11233C4E-18C5-4ACE-A2E0-B6055345755EQ36979349-2D4D6BFF-6190-46B3-9E8A-2F6A6E551D41Q37093045-05599D80-3831-44D1-A298-7159CF82B3B6Q37094045-52F5B534-9A18-475C-A709-C3EC569AA720Q37426994-6D146183-D0C6-4800-A2AE-604F6D1C8AF6Q37431197-CA7A60B4-7AE3-496D-9FAD-AEAA18B83AD0Q37506503-37509A43-EC44-44C2-8FA9-F8A71535F220Q37637283-888DA0A7-6CD8-4E21-A41B-BB2ADC0F3B1DQ37810994-BDFDF696-BFC3-49A5-88DE-003A09865560Q38100997-587CC40F-925A-45D7-9A1D-5A8C8CEE364BQ38166648-DF0AA90F-3D3D-465E-88D3-A0ED12ED5A28Q38230498-340B9225-845F-44A6-B1B3-47289EDEBE3AQ38767711-20A46054-F128-437C-814B-32A1D6DFAE40Q38805976-33446F6C-41D2-4499-8348-AC4A21D701DFQ39151291-CC434F4F-DF19-4EA0-8765-7A93A44B4F9BQ40994447-2B01FCCE-CB97-4BAF-A326-5A1CCA9E277CQ42444789-C0D6CF09-37BD-4F52-8586-838E0883A95DQ42496687-95C9DF47-5E8A-43CF-BA55-553356112DA5Q42515211-D41C6143-A5F6-45BC-80AA-91533773EF6CQ44078554-508CD452-0331-40A5-BF45-C876970785F3Q44185837-997BF71A-4D37-460D-902D-6BF1A8F53F37Q45859700-BC7E4141-D982-4C52-BE9B-26DD1B69759CQ46840734-A5909F75-1D26-45F9-935F-090E7E72659BQ47252951-AC589C09-EB8F-4F1A-B3B6-F8F5F0B853DFQ55426777-238AF8A6-4BC2-405F-AA69-38344B77B93CQ58913419-018D59CE-A2EF-4C44-BF97-C6F5641E371F
P2860
Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Lidocaine and muscimol microin ...... reverse Parkinsonian symptoms.
@ast
Lidocaine and muscimol microin ...... reverse Parkinsonian symptoms.
@en
Lidocaine and muscimol microin ...... reverse Parkinsonian symptoms.
@nl
type
label
Lidocaine and muscimol microin ...... reverse Parkinsonian symptoms.
@ast
Lidocaine and muscimol microin ...... reverse Parkinsonian symptoms.
@en
Lidocaine and muscimol microin ...... reverse Parkinsonian symptoms.
@nl
prefLabel
Lidocaine and muscimol microin ...... reverse Parkinsonian symptoms.
@ast
Lidocaine and muscimol microin ...... reverse Parkinsonian symptoms.
@en
Lidocaine and muscimol microin ...... reverse Parkinsonian symptoms.
@nl
P2093
P921
P356
P1433
P1476
Lidocaine and muscimol microin ...... reverse Parkinsonian symptoms.
@en
P2093
Dostrovsky JO
Hutchison WD
Pahapill P
Saint-Cyr J
P304
P356
10.1093/BRAIN/124.10.2105
P407
P577
2001-10-01T00:00:00Z